from achieving this goal. Be that as it may, a recent publication in the Lancet, entitled "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorders: a systemic review and network metaanalysis," would both challenge this pronouncement and suggest we already have effective antidepressants. 2 This recent study and several others purport that SSRI's do work in depression (but only perhaps in subtypes? -see later discussion) and that some older second-generation antidepressants (eg, amitriptyline)
showed greater efficacy, than many SSRI's. 2, 3 Thus, questioning the need for the next generation of "better" antidepressants and the need to step forward from historical dogma, redundant clinical classification, to a new era of neurobiology, neuronal networks of depression and precision pharmacology with its focussed on diagnosis based science not symptoms. [4] [5] [6] Given, the high failure rate of antidepressant clinical trials the proposition for better antidepressants remains in question, given that in the real-world antidepressants are only efficacious in 30%-40%
of depressed patients and probably in subpopulation yet to be Depressive disorders, in particular major depression disorder (MDD) is based on a 50-year-old monoamine hypothesis, questionable animal models and subjective clinical diagnostic criteria, with comorbidity across several neuropsychiatric disorders. 8, 9 Thus, the focus of this review is to ask the question(s) again, why are there so many failures and why so few successes and do we need "better" antidepressants? In this review, I want to build on what we've learned from the past and how this may lead us to future clinical successes in the treatment of depressive disorders. First, we need to understand the complexity this neuropsychiatric disorder, the global crisis, unmet medical needs, its current diagnosis, treatment, and future areas of research.
| G LOBAL DEPRE SS ION CRIS IS-THE UNME T MED I C AL NEED FOR B E T TER ANTIDEPRE SSANTS?
Depression is a significant contributor to the global burden of disease and affects people in all communities across the world requir- 
A recent World Health Assembly called on the World Health
Organization and its member states to take action in this direction.
https://www.cdc.gov/nchs/data/databriefs/db283_table.pd#4).
(http://www.who.int/mental_health/management/depression/ wfmh_paper_depression_wmhd_2012.pdf).
It is estimated that the prevalence of depression in the US is 15%
percent of the population reportedly taking an antidepressant-if not more. MDD is ranked fourth as a disease measured in disability adjusted for life years (DALYS) in 1990. 7, 10 Together with the fact that available antidepressant medications are ranked second behind ischemic heart disease as a potential disease burden by 2020. The risk for MDD, especially for females in developed countries, is 1 in 10. And, there is considerable evidence that depression is associated with increased risk for cardiovascular and infectious diseases as well as immunological and endocrine changes. The World Health Organization predicted that depression will become the leading cause of human disability by 2020. 11 It has been estimated that over a lifetime, the global prevalence of depression is 21.7% for females and 12.7% for males who suffer from depression at some point.
Epidemiological studies have estimated that 5%-9% of women and 2%-3% of men in the US suffer from depression at any time. 8 And, a Norwegian study showed that 24% of women suffer major depression at some point in their lives and 13.3% suffer from dysthymia, while 10% of males suffer from major depression at some point, and 6% suffer from dysthymia. 8 Depression in children and adolescents is a cause of substantial morbidity and mortality in this population, being a common disorder that affects 2% of children and up to 6% of adolescents 12, 13 . Although antidepressants are frequently | 3 of 20 used in the treatment of this disorder, there has been major controversy about the efficacy and safety of these medications in this population. 7 This led to the US food and Drug Administration (FDA) publishing a list of recommendations from the Psychopharmacologic
Drugs and Paediatric Advisory Committees over the years, including
many other neurological and psychotropic drugs.
This critical appraisal on the treatment of depression in children and adolescents is still an area of great concern and controversy in relation to the developing brain. Depression is a common condition with up to 8% of all teenagers having met criteria for depression in the last year. 14 In fact, by the age of 21 years, up to 14.8% of individuals have met criteria for a mood disorder. 13, 15 Some types of depression are familial, indicating that there is inherited vulnerability. 16 Similarly, in studies of families in which members of each generation develop bipolar affective disorder (BPAD) it has been found that those with the illness have a different genotype from those who do not become ill. Conversely, the reverse is not true: not all individuals with a purported BPAD genotype will develop the illness (epistasis-mutations in one gene masks a phenotype at another locus). That in additional to other factors, stresses at home, work, or school or other coping skills, are involved in the onset of the disease. In some families, major depression also seems cooccur generation after generation.
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A National Institutes of Mental Health (NIMH) National 
| CURRENT D IS E A S E S TATE AND D IAG NOS TI C CRITERIA
Depression is a very common medical condition that is associated with a wide range of emotional, cognitive, and physical symptoms.
Depressive disorders involve all major bodily functions, mood, and thoughts, affecting the ways in which a depressed individual, eats and feel about themselves, and thinks. Without treatment, depres- (Table 1) . 21, 22 Although these classifications have varying degrees of overlap and distinguishing features, their goal is to try and accurately classify the burden of patients suffering from mental disorders. However, the ferocious rhetoric regarding previous and the more recent DSM-5 and International
Classification of Disease (ICD-11) classification-promises and pitfalls is well documented with regard to the many flaws and discrepancies (see DSM-5 Pros and Cons.). 23, 24 In spite of the fact of the many changes and improvements in DSM-5 and ICD-11 from their predecessors, they both remain subjective categorical classification systems that are fundamentally descriptive in nature, based primarily on self-reported symptoms, clinically signs with observer bias and few supportive tests (eg, of intellectual functioning). The fact that since the early 1980's, research bodies e.g. NIMH and other funding agencies had virtually mandated the use of DSM or ICD diagnostic categories was argued as a major part of the problem. The DSM "Bible" was seen as dictating US mental health questioning its validity and widely denounced. What was needed was innovative thinking away from symptomatology-based diagnosis to an alternative approach. In 2009 the NIMH initiated the Research Domain Criteria (RDoc) project was deemed necessary, given the nascent state of the science of mental disorders and the conceptual and empirical constraints of research based on current classifications. The call was that research needed to break out from the straitjacket of current diagnosis.
The development of basic translational science applied to depression and other mental disorders responded slowly to the difficulties of the categorical classification system and represented a long-term NIMH endeavour. What the NIMH RDoc initiative brought to the forefront was the idea that to understand mental illness in all its complexity, the neuroscience field needs a research framework that accommodates the study of all causal factors together. This was acknowledged to be a long-haul and there are no right answers that this framework will work. The notion that neural-circuit based framework will ultimately deepen our understanding of the neurological, biological, psychological, social and cultural structures, and processes that underlie depression and mental illness will ultimately lead to a move away from an out-dated, systematic biases clinical trial methodology. 8, 25 Accordingly, Thomas Insel in proposing the NIMH's reorientation away from DSM categories stated, "We cannot succeed if we use DSM categories as the gold standard."
| MA JOR DEPRE SS IVE D ISORDER : DS M -5 SYMP TOMS OR ENDOPHENOT YPE S?
The symptom criteria for major depression according to the recent DSM-5 and ICD-11 guidelines are reported to be very similar although the coding systems are different.
The DSM-5 (Diagnostic and Statistical Manual of Mental
Disorders, 5 th Edition) has focussed on more attention genderspecific factors across disorders, cultural and cross-cultural assessments, Thus, the multi-axial system of psychiatric classification (ie, DSM-III, DSM-IV TF and ICD-10 see Table 1 ) is to be gradually replaced for all psychiatric and mental disorders that are now to be considered on a single axis. For example, in mood disorders the separation of bipolar and related disorders (BPAD) is a major change in diagnostic criteria and clinical descriptions forming a separate chapter for bipolar (affective) disorders (BPAD) in DSM-5 (see comprehensive reviews on BPAD in references 8, 26, 27 ).
In the case of depression, there are now 8 specific depressive disorders (single-axis) described in the DSM-5 (see below). With the aim of increasing the focus on these individual ("personalized") disorders, their severity, phenotypes/genotypes, and application of numerous specifiers to capture significant advances in clinical research, including advances in neurobiology and genetics. 
Premenstrual dysphoric disorder (PMDD)
5. Substance/medication-induced depressive disorder 6. Depressive disorder due to another medical condition
7.
Other specified depressive disorder
Unspecified depressive disorder
Adapted from: American Psychiatric Association (2013).
21,28
Whereas, DSM-IV comprised of additional subcategories for catatonic, melancholic, and atypical features and for postpartum onset. Both DSM-IV and ICD-10 present affective disorders together in one section, distinguishing bipolar (BPAD) from unipolar disorder (MDD), including dysthymia (see Table 1 ). Operational problems often encounted with ICD-10 include complexity, use of different clinical and research definitions, emphasis on single versus recurrent episodes, and the lack of some clinically useful subtypes.
Whereas, DSM-IV assigns separate unjustified categories of medical and substance-induced mood disorders and failed to code its useful qualifiers, 30 which now come under separate categories in DSM-5.
Also, within DSM-IV, bipolar disorder described a spectrum of disorders in which episodes of depression and mania occur, inter- (not merely self-reproach about being sick) 8. Diminished ability to think or concentrate, or indecisiveness (either by subjective account or observation of others) 9. Recurrent thoughts of death (not just fear of dying), or suicidal ideation, or a suicide attempt, or a specific plan for committing suicide B. The symptoms cause clinically significant distress or impairment in functioning. C. The symptoms are not due to a physical/organic factor or illness.
The symptoms are not better explained by bereavement (although this can be complicated by major depression)
| HYP OTHE S IS FAILURE: WHAT WE HAVE LE ARNT FROM THE PA S T, IF ANY THING?
The etiology of depression is unknown. Depression is polygenic in nature with both genetic and epigenetic components, making the use of genetically engineered animal as models for drug discovery unrealistic. 8, 9 This along with our emerging understanding of the complex biochemical mechanisms is compromised by the fact that most of the drugs used to treat depression and other neuropsychiatric disorders (eg, lithium and antidepressants in general) have ill-defined pleiotropic mechanisms of action with new signaling pathways and neuronal networks being identified, pointing to no "final common pathway" in the mode of action of antidepressant agents 
| THE MONOAMINE THEORY OF DEPRE SS ION-OF LIMITED SUCCE SS OR A DIS MAL FAILURE?
The longest-standing theory of depression is based on monoamine dysfunction and drugs acting on monoamine neurotransmission which has dominated the treatment of depression for over 50 years, albeit much maligned in recent times as a too simplistic and may have misguided our understanding of the complexity of the disorder. 8, 32 The fact remains, however, that the monoamine reuptake inhibitors and the MAOI's were shown to have antidepressant activity albeit by chance clinical observations and the discoveries of their modes of action were instrumental in developing the monoamine theory. 8 In the days when the monoamine theory of depression was evolving, the focus was more on norepinephrine (NE) than 5-HT Over 4 decades the therapeutic goal was to find, a fast-acting antidepressant. However, this was contended by Duman and a number of groups, that this approach may not be possible based on their neurogenesis hypothesis of antidepressant efficacy. 32, 34 To discover an antidepressant that has an effect within days rather than weeks has challenged researchers for decades to understand the reasons for the delay in onset of the antidepressant action. One theory based on the action of SSRI's is that inhibition of 5HT reuptake initially causes activation of the presynaptic 5HT 1A receptors on the cell bodies in the dorsal and median raphé nucleus. 8, 9 This inhibits the firing of 5-HT neurons, so reducing rather than increasing the release of 5HT from the terminals. 8, 9 According to this hypothesis first proposed as the primary mechanism of action of SSRI's due to an increased activation of 5-HT postsynaptic receptors in the forebrain and is not achieved until the raphé somatodendritic 5-HT 1A receptors become downregulated or desensitized. However, clinical molecular imaging and postmortem studies failed to find consistent evidence supporting alterations of in patients with MDD. 35 Furthermore, 5-HT 1A receptor antagonists also failed to achieve consistent clinical efficacy. as there is no clear evidence that the monoamine deficiency totally accounts for depression and questions the efficacy of monoaminebased agents. 8, 32 The question remains is there a single unifying mechanism underlying the complex manifestations of depression
In the case of MDD, genetic factors account for about 30% of the variance and environmental factors play a major role in inducing the illness. 36 The first direct evidence of the importance of variation in drug response was shown in depressed patients with a short form of the SERT promoter, who had a worse response to SSRI's than those with the long isoform. 8, 32 Other genes have been associated with antidepressant treatment and undoubtedly the field of pharmacogenomics and its application to the pathophysiological mechanisms of depressive disorders will continue to grow based on vulnerability gene environment interaction and experience-dependent biological systems that act cumulatively (eg, chronic stress) throughout an individual's lifetime. 29 That being said, the impact of genetics on mental disorders over the last few decades have been disappointing, despite the enthusiasm for new era of personalized medicine and an individual's genome. However, emerging results as discussed later may offer hope for future drug therapy based on endophenotype. 29 
| THE FAILURE OF E XPERIMENTAL DIS E A S E MODEL S OF DEPRE SS IVE DISORDER S?
Drug discovery in depression has been hampered by the lack of an universally accepted phenotypic screens-animal model(s) that can be used to screen NCEs for antidepressant -like effects. Animal models of depression have provided insights into mechanisms associated with MDD endophenotypes but how these models apply to human mental illness and its treatments remains difficult to assess.
Although there are several animal models that reproduce some features of depression in the context of stress and/or maternal separation, it is questionable as to whether these are relevant to the human disorder MDD or BPAD. The advantages and disadvantages of animal models for depression are summarized in various comprehensive reviews. 8, 37 However, in many cases, the behavioral features can be reversed by conventional antidepressant drug treatment. Despite this holistic notion and their intrinsic limitations, the full potential of these models has not yet been realized and they represent an underexplored opportunity. The heuristic value and the knowledge gain from behavioral animal models in psychopharmacology are, explicitly or implicitly, the central preoccupation of psychopharmacologists. 8, 9 There are a number of compelling reasons to believe in the legitimacy of animal models in the development of new improved drugs for the treatment of mental disorders; however, these models need to be based on the following criteria. 8, 9, 33 • Predictive validity: the ability of a model to accurately predict clinical efficacy of a psychoactive pharmacological agent.
• Face validity: the similarity of the model to clinical manifestations of phenomenon/disorder in terms of major behavioral and/or physiological symptoms and etiology.
• Construct validity: the strength of the theoretical rationale upon which the model is based
Animal models have been defined as experimental preparations developed in one species for the purpose of studying or understanding a phenomenon occurring in another species (eg, the "5-HT Syndrome" crosses a number of mammalian species).
In the case of animal models of human psychopathology, the aim is to develop syndromes that resemble those in humans in order to study selected aspects of neuropsychopharmacology. The behavioral models are explicitly related to a broader body of theory, as they fulfill a valuable function in forcing the clinician and psychopharmacologists alike to critically examine their assumptions of the manifestations and pathophysiology of depression and bipolar disorders. Importantly, they are still required to provide guidance on optimal dose level selection for clinical regulatory safety, general toxicological, and efficacy studies in humans. 33 To disparage phenotypic animal models of psychiatric disorders seems unwise today when many molecular manipulations (eg, Endophenotypic screening technology is revolutionizing drug discovery, such as CRISPR-based, multiple gRNAs can make multiple cuts to multiple genes simultaneously. The ability to do this for polygenic disorders could be revolutionary and a game-changer for the treatment of psychiatric disorders.
It is clear to all that the etiology of psychiatric disorders is still in its infancy; however, a healthy skepticism provides a valuable service in pointing out the many shortcomings when animal models are measured against the complexities of human behavior, more often or not when aligned to highly subjective clinical data. autophagy. 33 Recent siRNA-mediated knockdown of the SERT in the adult mouse and rat brain would support the concept, although selectivity and side effects remain an issue. 33, 38 Other recent methodologies include, antidepressant drug "signatures" using pharmacodynamic EEG measurements in animals and human studies as a measure of "antidepressant efficacy" and more recently with pharmacodynamic changes in EEG gamma oscillations. 39, 40 Finally, the rapid progress in mutated mice studies using CRISPR/ Cas9 gene editing technology, 41 has shown that that differentiation of receptor subtypes can now be achieved for example, the delta subtype GABA A receptor contributes to the antidepressant effects observed in these mice. Supporting, the positive antidepressant activity observed in Phase II/III clinical studies in postpartum depression (PPD)
with the GABA A positive allosteric agonist (PAM) brexanolone-SAGE -547. 42 The FDA recently approved this intravenous drug, as the first treatment for PPD(https://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm633919.htm). A second SAGE compound is currently in a Phase III, study which is a more bioavailable inhibitory pregnane neurosteroid analogue -SAGE-217 (3α-Hydroxy- 
| OTHER NEURO CHEMI C AL THEORIE S OF DEPRE SS ION

| Neurogenesis: creation of new neurones critical to antidepressant action?
Antidepressant treatments, such as SSRIs and electroconvulsive shock (equivalent to human electroconvulsive therapy, ECT) increase neurogenesis specifically in the hippocampus. 45 In fact, the maturation period for neurogenesis in the dentate gyrus appears consistent with the delay for the full therapeutic effects of antidepressants, as previous reported in the seminal work of Duman. [46] [47] [48] Thus, these preclinical findings suggest that adult neurogenesis may be modulated by factors associated with MDD, including chronic stress, 49 and activation of the HPA axis. 50 While the evidence reviewed above suggests the presence of a link between reduced hippocampal adult neurogenesis and MDD, preclinical and clinical studies have also reported findings that are inconsistent with this hypothesis. 51 While chronic fluoxetine treatment doubled the number of new hippocampal neurons in normal mice, it had no effect in 5-HT 1A knockout mice. The tricyclic imipramine boosted neurogenesis in both types of mice, indicating that the 5HT 1A receptor is required for neurogenesis induced by fluoxetine but not imipramine. Chronic treatment with a 5HT 1A selective drug confirmed that activating the 5HT 1A receptor is sufficient to spur cell proliferation. An extension of this work using the SSRI fluoxetine in a transgenic cell line from dentate gyrus showed that the SSRI does not affect division of stemlike cells but increases division of amplifying neuroprogenitor cells that results in new neurons in dentate gyrus. This effect was specific for dentate gyrus. 52 These results suggest that strategies aimed at stimulating hippocampal neurogenesis provide novel avenues for the treatment of anxiety and depressive disorders. However, the "Holy Grail" of current treatment strategies is to develop antidepressants with a fast onset of action. In this light, the neurogenesis hypothesis would therefore not support this approach. However, this theory is now in question with regard to the fast-onset and long duration of efficacy observed with ketamine-like agents (see later and Table 3 ). 
TA B L E 3 Types bipolar affective disorder (BPAD)
a
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Thus, with other clinical data still awaited the jury is still out for ketamine-like drugs being the "next generation" of rapidly acting antidepressant drugs Table 4 . (see., 64 for an excellent review of glutamate signaling in depression).
In summary, given the overall complexity of the underlying neurochemical changes attribute to the pathophysiology of depressive disorders and the recent single axis DSM-5 classification of depressive disorders, raises questions concerning the validity "fit-for-purpose" animal models of depression and their ability to mimic monoaminergic and non-monoamine approaches in antidepressant drug development. In retrospect, despite the criticism and controversy attached to them, which is largely based on subjective assessment criteria much like categorical classification systems that are fundamentally descriptive-as described in the various complex DSM/ICD "specifier" criterion. Therefore, some would argue that with insufficient evidence at present to align emerging neurobiological technologies related to animal models, disease pathologies/ neurocircuitry and endophenotypes, it will take time before they eventually become congruent and play an increasing part in antidepressant drug development in the future (see above). 
| CLINI C AL TRIAL FAILURE S AND FUTURE CHALLENG E S
67-69
The use of meta-analysis for evidence-based treatment depends on which study you read as to the efficacy of antidepressant agents, in particular for SSRI's. The previous guideline as discussed, were far from optimal and barely cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, maintenance treatment to prevent recurrence, and the increasing importance of discontinuation of treatment.
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A recent report indicated that it is not uncommon that withdrawal (discontinuation syndrome) effects from antidepressants can last for several weeks or months, 72 supporting earlier findings. 
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A more recent study critical of the clinical relevance of the HAMD-17 diagnosis criteria, argue that frequent using HDRS-17-sum scores, used as an effect parameter may have distorted the current view on the usefulness of SSRIs and hampered the development of novel antidepressants. 3 Firstly, these authors argued that HDRS-17 is multidimensional, indicating that relevant improvement in one domain of symptoms may be masked, due to enhanced variability, by lack of improvement in other less relevant domains. Second, the included symptoms differ in terms of burden of illness and many of them correlate poorly with depression severity. Third, some items refer to several heterogeneous symptoms, and the different grades for a certain item do not always represent differences in severity but qualitatively distinct phenomena; both these aspects may contribute to the poor interrater reliability marring the reliability of the instrument. Fourth, many patients reporting some of the symptoms to be absent already at baseline is bound to reduce the sensitivity of the instrument by enhancing variability, as is the fact that some of the symptoms, such as backaches and headache, are common also in nondepressed subjects, and may therefore be present also after recovery. 
| CLINI C AL TRIAL DE S I G N: THE ROLE OF PL ACEBO RE S P ON S E AND OUT COME ME A SURE S?
Over the last 30 years, the randomized, double-blind, placebo- yields 75% empirical power compared with 50% for LOCF. is simple to use, easy to implement, and to specify a priori. It is also more likely than LOCF to give adequate control of type I (false-positive) and type II (false-negative) errors. In other words, the use of either MMRM or LOCF will lead to the same conclusions but MMRM is likely to yield fewer mis-steps along the way according to some groups. 80 An extension of the MMRM, the novel nonlinear NLMMRM provides a tool for assessing a weighting factor collected from various centres thereby controlling the confounding effect of high placebo response across sites, to increase signal detection and to provide a more reliable estimate of the "true treatment effect" (TE) by controlling false negative results associated with excessively high placebo. 81 To date, few if any, published comparative study of newer antidepressants has enrolled a sufficiently large group of patients to have the power to reliably detect the differences between 2 effective treatments according to a recent critique. 74 One exception to this is the NIMH-sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project, which enrolled 5000 patients is a comparative treatment trial. 82, 83 Although, some might argue that in the STAR*D study, patients with comorbid disorders and lower levels of depression severity were included with placebo control group, a perceived limitation of the study. And, therefore, no firm conclusion can be drawn on the effectiveness of the medications in this broad population of patients. 83 Unfortunately, owing to the cost and resources required to conduct studies of sufficient size, the average RCT evaluating antidepressant effects is woefully underpowered. For example, in a recent review of 186 RCTs examining the efficacy and tolerability of amitriptyline in comparison with other antidepressants, the average number of patients per treatment group was . In an analysis of pivotal studies (ie, well-designed, well-controlled studies on which the FDA bases decisions about the efficacy of NCEs) for 7 newer antidepressants, only 65-75 patients were included per study arm. 74 Thus, the average study comparing 2 effective antidepressants would have less than 20% power to find a real, albeit modest (ie, 10%), difference in response rates. Put another way, the likelihood of a false-negative finding (ie, a type II error) would be 4 times greater than the chance of observing a statistically significant difference.
It is apparent that specific treatment effects have declined in recent decades. This may be due to selection bias at work that differs from that of a generation ago. The sample size, the number of centers, treatment arms, dosing (eg, flexible dosing versus fixed), and different expectation biases all potentially influence results. For example, in the 1960s, more trials evaluated hospitalized patients who are less responsive to placebo and who have a more robust response to antidepressants. 74 Beyond the issue of inpatient/outpatient status, older studies were more likely to enroll patients with more severe forms of depression, BPAD, psychosis, and recurrent melancholic subtypes of depression. In addition, the efficacy of antidepressant interventions was less well understood then (which may have lowered expectations of the patient or clinician) and fewer potential participants had ever received an effective course of pharmacotherapy.
Contemporary trials, on the other hand, may be enrolling a different population: highly selected ambulatory less severe depressed patients who are often contacted through the mass media.
Thus, these subjects may be less severely depressed and are rarely treatment naïve. 74 Attempts to lessen these problems by restricting enrolment to patients with relatively high levels of pretreatment severity have often, in fact, accentuated them by inadvertently causing an inflation of entry depression scores. 74 Many clinical trials use entry criteria based in part on a minimum score for the same instrument used to evaluate efficacy. Investigators may be motivated, consciously or not, to increase baseline scores slightly in order to enter subjects into the trial. Such scores may then decrease by that same amount once the subject is entered, thus contributing to what appears to be a placebo effect-if not analyzed appropriately.
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Another factor influencing the apparent effectiveness of antidepressants aside from the placebo-effect is the so-called "file-drawer effect": the bias introduced by the tendency to publish positive but not negative studies. This bias is most evident when comparing reviews of published studies with reports that are based on data sets that have been submitted to the FDA for regulatory review. 74 For example, on the basis of studies conducted for the registration of new antidepressants from fluoxetine to citalopram the effects of antidepressants appear to be only about half the size (relative to placebo)
once the unpublished studies are considered.
| NE W INITIATIVE S OF CONDUC TING AND E VALUATING CLINI C AL TRIAL S
A number of recent encouraging statements from FDA on advancing 
| Bridging studies
In a "bridging study," dosage is optimized early in development by determining the maximum tolerated dose of a compound in patients.
Consecutive panels of patients each receive higher doses of study drug until a minimum in-tolerated dose is reached. The dose immediately below this one is then considered the maximum tolerated dose.
Careful subject selection, adequate facilities, and highly qualified, 
| Study trial length
Although there is much controversy in the clinical community, a review of the 6 most commonly prescribed antidepressants found that efficacy studies were virtually always short-term, rarely exceeding | 15 of 20 12 weeks of treatment. [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] Hence, it can be argued that in the real world, the clinical value derived from such studies remains restricted and suboptimal. Thus, only 18% of the observed changes during these short-term studies in patients with nonsevere forms of depression could be attributed to the active effects of medication.
Active medication and placebo both shared 82% of the maximum clinical changes observed, leading to the conclusion that, assuming the effects of the antidepressant medication and placebo are additives, the effects of the medication, even in this clinically favorable group (very few or no psychotic or suicidal participants, very little comorbidity), is extremely modest, negligible, and potentially of little clinical significance. In summary, such studies strike at the core of our understanding of neuropsychopharmacology drug development. Indeed, there has been considerable debate as to the nature of these analyses and how they can be best interpreted to achieve success rather than failure. 80, 81 However, the single most comforting suggestion for psychopharmacology is that the powerful antidepressant effects of these drugs are actually masked by the inadequacy of current clinical trial designs and that the research strategy for the evaluation of novel psychotropic agents, according to Matthews and colleagues over a decade ago, needs significant rethinking and reevaluation. 8 One immediate and possible solution to de-risking clinical trial design failure would be the availability of robust biomarkers but presently there are no approved biomarkers for MDD (see below). 89 
| Biomarkers for Depressive Disorders?
The main uses of biomarkers for drug development are:
• discovery and selection of lead NCEs;
• generation of pharmacokinetic (PK) and pharmacodynamic (PD) models;
• aid in clinical trial design and expedite drug development;
• serving as surrogates for clinical or mortality endpoints;
• optimizing drug therapy based on genotypic or phenotypic factors; and
• definition of patient enrolment in studies and help with stratification (biosignature development).
A major factor in the development of "better" antidepressants has been the lack of robust biomarkers, which has seriously limited prog- patients and enabling the development of diagnostic classifiers (biomarkers) that most likely will target specific patient phenotypes. 89, 91 The validation of these assessments against relevant biomarkers, across large multi-site studies will add to their cogency. Trace Amines-TAAR1. Aside from these recent advances, the number one challenge remains to develop novel antidepressants with greater efficacy and rapid action (see section on ketamine, Table 4 
| CON CLUS ION
Although we live amid a game-changing revolution in neuroscience Therefore, as we emerge from this conceptual neurobiological revolution, the integrity and validity of epigenetic data, imaging brain neurocircuitry, molecular and structural insights, will become increasingly important in guiding optimal diagnosis, prediction of treatment responses in the discovery, and development of "better"
antidepressants. 
